Bayer announces that it has acquired Blackford Analysis Ltd, an imaging artificial intelligence (AI) platform and solutions provider. The acquisition is part of Bayer’s strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to improve patient care and advance Bayer’s position in digital medical imaging.
“Adding Blackford and its AI technology to our radiology portfolio secures Bayer an excellent position in the fastest-growing segment within the overall global radiology industry,” says Stefan Oelrich, member of the board of management, Bayer AG and president of Bayer’s pharmaceutical division. “This acquisition complements our comprehensive radiology portfolio and nourishes our engagement to drive innovation in digital health.
Oelrich adds, “We are pleased to join forces with Blackford and their exceptional team to optimally utilize our combined expertise in healthcare technology with the aim to deliver true value to radiologists and their teams for the benefit of their patients.”
Blackford, which has a presence in the United Kingdom and the United States, provides infrastructure and access to a clinical application (ClinApp) ecosystem focused on imaging and analytics. The acquisition follows a development and license agreement between both companies in 2020 that laid the foundation for Bayer’s recently launched medical imaging platform, Calantic Digital Solutions. Building on technology from Blackford and adding additional workflow and analytics components, Calantic Digital Solutions delivers access to applications, including those enabled by AI, for medical imaging.
Blackford will remain accountable to advance its technology, channel partnerships and ClinApp portfolio while benefiting from the experience, infrastructure, and reach of Bayer as a global pharmaceutical company, according to company officials. The acquisition is expected to close later this year, pending the satisfaction of customary closing conditions.
“Blackford exists to improve the lives of patients and populations by unlocking the adoption and benefits of medical imaging AI. We investigated many routes to scale our business to deliver our mission and were delighted by Bayer’s invitation to deepen our partnership, while continuing to operate independently based on Bayer’s well-established arm’s length model,” says Ben Panter, CEO of Blackford Analysis.
“Combining our knowledge and experience as one of the leading platform providers in the industry with Bayer’s advanced radiology portfolio will enable us to provide solutions to deliver ongoing clinical value to radiologists and their teams,” Panter adds.